Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

PHASE4TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

May 29, 2015

Study Completion Date

May 29, 2015

Conditions
Psoriasis
Interventions
DRUG

Etanercept

Administered by subcutaneous injection

Trial Locations (47)

14625

Research Site, Rochester

15213

Research Site, Pittsburgh

19462

Research Site, Plymouth Meeting

23507

Research Site, Norfolk

29414

Research Site, Charleston

30342

Research Site, Atlanta

31217

Research Site, Macon

32204

Research Site, Jacksonville

33136

Research Site, Miami

33607

Research Site, Tampa

33609

Research Site, Tampa

33708

Research Site, St. Petersburg

35205

Research Site, Birmingham

36609

Research Site, Mobile

37215

Research Site, Nashville

37917

Research Site, Knoxville

38134

Research Site, Bartlett

40202

Research Site, Louisville

46168

Research Site, Plainfield

47150

Research Site, New Albany

60077

Research Site, Skokie

63117

Research Site, St Louis

68144

Research Site, Omaha

70112

Research Site, New Orleans

75231

Research Site, Dallas

77004

Research Site, Houston

80220

Research Site, Denver

85044

Research Site, Phoenix

90045

Research Site, Los Angeles

90404

Research Site, Santa Monica

91436

Research Site, Encino

92697

Research Site, Irvine

93309

Research Site, Bakersfield

94118

Research Site, San Francisco

94583

Research Site, San Ramon

95816

Research Site, Sacramento

99362

Research Site, Walla Walla

06030

Research Site, Farmington

02115

Research Site, Boston

08520

Research Site, East Windsor

07044

Research Site, Verona

02919

Research Site, Johnston

R3C 0N2

Research Site, Winnipeg

B3H 0A2

Research Site, Halifax

L3P 1X2

Research Site, Markham

K9J 1Z2

Research Site, Peterborough

N2J 1C4

Research Site, Waterloo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01543204 - Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab | Biotech Hunter | Biotech Hunter